Table of Contents — Dec 2011 - 8th International Symposium on Advanced Ovarian Cancer: Optimal Therapy 4 Mar 2011, Valencia Spain

Blogger's Note: abstracts - subscription req'd ($$$) to access full view symposium articles

1. R. C. Bast, Jr Molecular approaches to personalizing management of ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii5-viii15 doi:10.1093/annonc/mdr516 
2. N. Urban Designing early detection programs for ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii6-viii18 doi:10.1093/annonc/mdr472 
3. N. F. Hacker Quality control in ovarian cancer surgery Ann Oncol (2011) 22(Suppl 8): viii19-viii22 doi:10.1093/annonc/mdr517 S. 
4. Kang and S.-Y. Park To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii23-viii28 doi:10.1093/annonc/mdr530 
5. N. Katsumata Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor Ann Oncol (2011) 22(Suppl 8): viii29-viii32 doi:10.1093/annonc/mdr468 
6. M. E. L. van der Burg, I. A. Boere, and P. M. J. J. Berns Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra Ann Oncol (2011) 22(Suppl 8): viii33-viii39 doi:10.1093/annonc/mdr514 
7. S. Pignata, L. Cannella, D. Leopardo, G. S. Bruni, G. Facchini, and C. Pisano Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up Ann Oncol (2011) 22(Suppl 8): viii40-viii44 doi:10.1093/annonc/mdr470 
8. G. J. S. Rustin Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed Ann Oncol (2011) 22(Suppl 8): viii45-viii48 doi:10.1093/annonc/mdr471 
9. E. A. Eisenhauer Optimal assessment of response in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii49-viii51 doi:10.1093/annonc/mdr467 
10. Michael A. Bookman Update of randomized trials in first-line treatment Ann Oncol (2011) 22(Suppl 8): Viii52-viii60 doi:10.1093/annonc/mdr466 
11. E. Pujade-Lauraine and J. Alexandre Update of randomized trials in recurrent disease Ann Oncol (2011) 22(Suppl 8): viii61-viii64 doi:10.1093/annonc/mdr518 
12. R. A. Burger Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii65-viii68 doi:10.1093/annonc/mdr529 
13. M. Markman The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy Ann Oncol (2011) 22(Suppl 8): viii69-viii71 doi:10.1093/annonc/mdr469 
14. C. Sessa Update on PARP1 inhibitors in ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii72-viii76 doi:10.1093/annonc/mdr528 K. 
15. Bell-McGuinn, J. Konner, W. Tew, and D. R. Spriggs New drugs for ovarian cancer Ann Oncol (2011) 22(Suppl 8): viii77-viii82 doi:10.1093/annonc/mdr531

conference notice: Welcome to the 12th International Congress of Human Genetics annual meeting (Montreal)

On behalf of The American Society of Human Genetics (ASHG) and the International Federation of Human Genetics Societies (IFHGS), it gives us great pleasure to invite human geneticists from all around the world to attend and participate in the 12th International Congress of Human Genetics (ICHG) and the 61st ASHG Annual Meeting. The Congress will be held at the Le Palais des Congrès (Convention Center) in Montreal (Quebec), Canada from Tuesday, October 11th through Saturday, October 15th 2011, coinciding with the ASHG meeting.

The ICHG is the foremost meeting of the world human genetics community and is held every five years. The first Congress was held in 1956 in Copenhagen and subsequent venues have included Berlin, Washington, DC, Rio de Janeiro, Vienna and most recently Brisbane. The anticipated attendance is 7,000 delegates from over 60 countries around the world.

Doctors 2.0 conference Paris 2011 - Speakers (includes Gilles Frydman/ACOR)

Speakers include:

Gilles Frydman is the head of ACOR, the Association of Cancer Online Resources, founded in 1995 in New York, and the largest online cancer patient community with 65 000 patients and caregivers. ACOR’s 159 electronic lists deliver approximately 1.5 million email messages weekly. The ACOR community has demonstrated its ability to accelerate the distribution of quality information regarding trials, treatments, pharmacovigilance.

SGO Annual Meeting on Women's Cancer

scroll down page to pdf file: Final Program

Imedex: Great Debates & Updates in Gynecologic Malignancies April 9, 2011 New York, New York conference notice

OCNA 2010-2011 series 2010-2011 Webinar(s)/registration form

Advancing Ethical Research Conference - December 2010

Women's Health in Asia | The Lancet Conferences Dec 2-5th announcement

Ovarian Cancer Tweets about........ selected slide re: OCATS/Regina conference

Editorial :: Cochrane in the United States of America - The Cochrane Collaboration (background/2010 Keystone, Colorado conference)

 Note: The Gynecologic Cancer Review Group section of the Cochrane is based out of the UK. Consumer reviewers may participate irrespective of geographic location as the Cochrane is primarily internet-based.


"On 18 October 2010, the first joint Colloquium between the Campbell and Cochrane Collaborations opens in Keystone, Colorado, USA. The USA last hosted the Cochrane Collaboration Colloquium and annual meeting in 1998 in Baltimore, Maryland. The Colloquium's return to the USA comes on the heels of President Obama's signing of historic health care reform legislation. As reported, "the reforms, which will cost an estimated USD 940 billion over 10 years, will expand the provision of care to 32 million more people, predominantly the poorest, and will result in the country achieving 95% coverage" (MacAskill 2010). At the same time The American Recovery and Reinvestment Act of 2009 has provided USD 1.1 billion for Comparative Effectiveness Research (CER), and established the Patient-Centered Outcomes Research Institute (PCORI). PCORI will make a major annual investment in CER, through the National Institutes of Health (NIH) and the Agency for Healthcare Research and Quality (AHRQ).

The US contribution to the development of The Cochrane Collaboration has been considerable. US-based researchers represented 7/84 (8.3%) of the pioneers attending the first Cochrane Colloquium in October 1993........."cont'd

AGENDA: Conference September 24th: Gynecologic Cancer Conference, Regina, Saskatchewan

      website:   http://www.ocats.ca

registration:  

http://www.cvent.com/EVENTS/Info/Summary.aspx?e=ce9c4a0f-157e-4a42-ab49-0f19dae902e3

September 24th, 2010 AGENDA

7:45 a.m. – 8:45 a.m. Conference Registration & Continental Breakfast
Exhibit Hall Marketplace Open

9:00 a.m. – 9:15 a.m. Welcome!
Official opening of the first Saskatchewan Gynecologic Cancer Conference
Greetings from Co-Chair Scott Livingstone, Executive Director of the Saskatchewan Cancer Agency

9:15 a.m. – 10:00 a.m. Opening Keynote Speaker -
Rosalee Longmoore, President -  Saskatchewan Union of Nurses
Nurses are integral health care providers for the gynecologic cancer patient and her family, every step of the way. Ms. Longmoore will describe the dedication of nurses to the advancement of patient care and how they can add to the patient and her family’s quality of life.

10:00 a.m. – 10:30 a.m. Dr. Vicki Holmes
 Women’s Mid-Life Health Centre of Saskatchewan 

Dr. Vicki Holmes’ presentation will focus on the role of the General Practitioner in encouraging women to report symptoms, interpretation symptoms, the use of appropriate diagnostic tests and examinations of women of all ages, proper referral to specialists and support during and post treatment.  Although the patient’s primary physician at the hospital is likely to be her gynecologic oncologist, the family doctor still plays a key role in the patient’s care and treatment for pre diagnosis to post treatment.  New thoughts and methodologies for medical care, testing, diagnosis and treatment have required today’s doctors to be more involved and aware of symptoms for young girls to senior citizens.

10:30 a.m - 11:00 a.m  Nutritious Break
Exhibit Hall Marketplace Open

11:00 a.m. – 12:00 p.m Panel Presentations

Andrew Gilbertson, Pharmacist – Managing Medication
The role of your pharmacist in family health and managing your medication.

Dr. Heather Fox – Complementary/Alternative Therapies
Presenting non-traditional methods of diagnosing, preventing and treating cancer.

Monica Milas – Support for the emotional side effects of cancer and treatment
The side effects of gynecologic cancer and it's affect on survivors and their partners. Learning how to overcome these issues. 

12:00 noon – 1:00 p.m. Organic Lunch

Exhibit Hall Marketplace Open

1:00 p.m. – 2:00 p.m. Scott Livingstone,
Executive Director of the Saskatchewan Cancer Agency 
Gyneocology Cancer Program in Saskatchewan

2:00 p.m. – 3:00 p.m. Panel Presentation

Dr. Muhammad Salim – Clinical Trials
Dr. Salim is the head of clinical trials in Saskatchewan, and the only Canadian
doctor on a team at the Mayo clinic for clinical trials – Learn about the basics of
clinical trials and their importance.

Dr. Christopher Giede - When cancer returns
Learn about the medical options available to survivors facing recurrence and review
ways you can work with your medical team to make well-informed decisions about
your treatment.

Wendi Stoeber, RN, MA, CCGC - Genetic Counsellor
Learn about ovarian cancer genetics and how to identify families who may be at
heredity risk for the disease. Review the benefits, the risks and limitations of
genetic testing for ovarian cancer.

3:00 p.m. to 3:15 p.m. Nutritious Break

Exhibit Hall Marketplace Open

3:15 p.m. to 4:15 p.m. Closing Speaker – Sandi Pniauskas
Sandi Pniauskas is an ovarian cancer survivor and is considered one of the
strongest and most vocal advocates for ovarian cancer women and their families.

4:15 p.m. to 4:30 p.m. Closing Remarks, Co-Chair Darlene Gray

Benefit Gala & Silent Auction

6:00 p.m.      Cocktails & Silent Auction opens

7:00 p.m.      Dinner is Served

8:00 p.m.      Presentations & Dessert

8:30 p.m.      An Intimate Evening with Jack Semple

American Institute for Cancer Research (AICR): AICR Cancer Research Conference Oct 21/22, Washington, DC

Food, Nutrition, Physical Activity and Cancer
October 21 & 22, 2010 | Capital Hilton Hotel, Washington, DC

Who Should Attend

Basic scientists, clinical investigators, epidemiologists, dietitians, nutritionists, policy makers and other health professionals interested in food, nutrition, physical activity and weight management in relation to cancer.